ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
Tarek M. Abdel-Fatah(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Katia A. Mesquita(University of Nottingham), Graham Ball(Computer Algorithms for Medicine), Maaz Tahir Sadiq(Queen Elizabeth Hospital Birmingham), Reem Ali(Hamad bin Khalifa University), Andrew R. Green(Nottingham Biomedical Research Centre), Stephen Chan(Heidelberg University), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
Cited by 13
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639